Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    etirinotecan pegol
Show Display Options
Rank Status Study
1 Active, not recruiting Etirinotecan Pegol (NKTR-102) in NSCLC
Conditions: Metastatic Non Small Cell Lung Cancer;   Recurrent Non Small Cell Lung Cancer
Intervention: Drug: Etirinotecan pegol (NKTR-102)
2 Recruiting Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Tumors Metastatic to Brain;   Metastatic Breast Cancer
Interventions: Drug: pegylated irinotecan NKTR 102;   Other: laboratory biomarker analysis
3 Completed A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Conditions: Advanced Cancer;   Metastatic Solid Tumors
Intervention: Drug: NKTR-102
4 Recruiting A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
Condition: Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
Interventions: Drug: 145 mg/m2 NKTR 102;   Drug: 120 mg/m2 NKTR 102;   Drug: 50 mg/m2 NKTR 102
5 Completed
Has Results
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Conditions: Anaplastic Astrocytomas;   Anaplastic Oligodendrogliomas;   Glioblastomas (GBM)
Intervention: Drug: Etirinotecan pegol
6 Recruiting A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Conditions: Metastasis;   Breast Cancer
Interventions: Drug: NKTR-102;   Drug: Eribulin;   Drug: Ixabepilone;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Nab-paclitaxel
7 Active, not recruiting Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Irinotecan;   Other: Pharmacological Study

Study has passed its completion date and status has not been verified in more than two years.